Incorporating Precision Medicine into Oncology

Video

In Partnership With:

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Terrill Jordan, LLM, JD, president and chief executive officer, Regional Cancer Care Associates, discusses challenges regarding the utility of precision medicine in oncology.

There is a robust pipeline of drugs in development in oncology, explains Jordan. The number of agents that are poised to enter the market may complicate current treatment strategies.

Notably, precision medicine has helped individualize treatment for patients. Among the flood of new agents, physicians should consider patient-specific factors when choosing a treatment.

Precision medicine can be costly; however, it appears to be cost-effective in the long-term, concludes Jordan.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD